Actinium names Jennifer Liberi Director of Clinical Operations

Actinium Pharmaceuticals has announced that it has named Jennifer Liberi Director of Clinical Operations.

Actinium is a biopharmaceutical company the focuses on the development of immunotherapies designed to treat advanced cancers.

Liberi’s responsibilities will include managing the company’s clinical trials, as well as training and leading sites conducting these trials, external service providers and the staff at each facility. She will report directly to Actinium’s Head of Clinical Development and SVP, Felix Garzon, M.D., Ph.D.

Prior to her appointment at Actinium, Liberi worked as the Director of Clinical operations at Noven. During her time at Noven, she organized and oversaw clinical trials, Phases 1 through 4, and made certain that budgets and timeframes associated with the projects were followed. Liberi also prepared and reviewed protocols, consent forms, case report forms and other types of documentation that is associated with clinical trials. She also handled the selection process and directed outside service providers.

Before her time with Noven, Liberi worked with international pharmaceutical companies for 10 years in various positions of increasing importance. These companies include Merck Research Laboratories, Novartis, Hoffman La-Roche and Bristol-Myers Squibb. Liberi received her bachelor of arts degree from Monmouth University.